Dupilumab biosimilar (Chengdu Kanghong)

度普利尤单抗生物类似药(成都康弘)

Report date: 2026/01/23 11:41:17

Base Information

Drug NameDupilumab biosimilar (Chengdu Kanghong)
Drug Alias NameKH816KH-816
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-13Interleukin-4Interleukin-4 receptor subunit alpha
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChengdu Kanghong Biotechnologies Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Kanghong Biotechnologies Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A